AbCellera Biologics reported positive top-line Phase 2 data for ABCL635, an investigational non-hormonal antibody therapy targeting the neurokinin 3 receptor, or NK3R, for moderate-to-severe menopausal vasomotor symptoms. In a Phase 1/2 trial of 92 postmenopausal women, a single 600 mg dose significantly reduced hot flash frequency and severity versus placebo at four weeks, while also improving sleep and patient global impression of change. Shares rose sharply on the news, with one report citing a 24% premarket gain and another showing the stock up 33.26% to $9.23 later on Monday.